| Background and Aims: Liver failure (LF) associated with HBV is life-threatening, and currently, it is controversial that whether nucleos(t)ide analogues (NA) could improve the outcomes of this disease. To evaluate the efficacy of NA in the treatment for LF due to HBV compared with the therapies without any antiviral medication.Methods: We searched PubMed, Medline, the Cochrane Collaboration, CNKI (National Knowledge Infrastructure), VIP database, 20 eligible studies were involved in this meta-analysis (treatment groups:778/control groups:801). The related data was analyzed by using the Review Manager Software 4.2. Both the quality of the included studies and the heterogeneity were examined.Results: The antiviral therapy with nucleoside analogues (NA) could enhance the survival rate of people with LF associated with HBV: combined effect of the RR was 1.48, 95%CI(1.25,1.75), P<0.05, comparing with the control groups. Separated comparison about lamivudine and entecavir were taken, both of the two medications presented beneficial effects for LF due to HBV, combined effects of RR were: LAM groups RR=1.60, P<0.05; ETV groups RR=1.34, P<0.05). Comparing with blank control groups, the impact of different time to start the NA treatment was also analyzed: at early and medium stage of liver failure, NA groups showed an obvious advantage over enhancing the survival rate (combined effects of RR: Early stage RR=1.51, P<0.05; Medium stage RR=2.03, P<0.05).Conclusions: Among patients suffered from liver failure due to HBV, antiviral therapy with nucleoside analogues (NA) could enhance the survival rate. If there is no contraindication, the NA should be given to the patients as soon as possible. |
